Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD1a CAR-T for r/r T-ALL/LBL
NCT05745181Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Feb 2023
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OC-1 in T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LL), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Objective Response Rate at 1 year, Progression-Free Survival at 1 year and 2 more. Started Feb 2023; status: recruiting.
02
Drugs
OC-1
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT05745181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745181.